Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17895705 | 0.91 | RORC (0.39) | RORCKCNA5RAB9ANPC1CYP1A2 | |
| SCHEMBL17895611 | 0.90 | PIK3CA (0.39) | RORCRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL17895681 | 0.87 | NPC1 (0.38) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17895693 | 0.86 | PPARA (0.38) | RORCKCNA5RAB9ANPC1CYP1A2 | |
| SCHEMBL17895625 | 0.85 | CASR (0.44) | KCNA5RAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL17895651 | 0.85 | RAB9A (0.36) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17895599 | 0.83 | PPARA (0.38) | RORCRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL17895668 | 0.83 | CASR (0.46) | RORCRAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL17895688 | 0.82 | PIK3CG (0.38) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17895671 | 0.81 | PPARA (0.40) | RORCRAB9ANPC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434234-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2022-09-06 | — | — | US | claimed |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. | 2021-10-21 | — | — | US | claimed |
| US-10851095-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2020-12-01 | — | — | US | claimed |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2019-08-22 | — | — | US | claimed |
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2018-01-04 | — | — | US | claimed |
| EP-3240778-A1 | METHODS AND AGENTS FOR TREATING DISEASE | Angion Biomedica Corp. (US) | 2017-11-08 | — | — | EP | claimed |
| WO-2016109492-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP (US) | 2016-07-07 | — | — | WO | claimed |
| US-11434234-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. | 2021-10-21 | — | — | US | disclosed |
| CN-107531631-B | Methods and agents for treating diseases | 安吉昂生物医药公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10851095-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10287282-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3240778-A1 | METHODS AND AGENTS FOR TREATING DISEASE | Angion Biomedica Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109492-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | RORC 326/4885KCNA5 2126/4885RAB9A 2203/4885 |
| US-11434234-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | RORC 421/4885KCNA5 2535/4885RAB9A 2120/4885 |
| US-10851095-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | RORC 421/4885KCNA5 2535/4885RAB9A 2120/4885 |
| US-10287282-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | RORC 326/4885KCNA5 2126/4885RAB9A 2203/4885 |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | RORC 421/4885KCNA5 2535/4885RAB9A 2120/4885 |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | RORC 421/4885KCNA5 2535/4885RAB9A 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.